Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.
Identifieur interne : 001252 ( PubMed/Checkpoint ); précédent : 001251; suivant : 001253Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.
Auteurs : Brad Hagen [Canada] ; Chris Armstrong Esther ; Roland Ikuta ; Robert J. Williams ; Carole-Lynne Le Navenec ; Morgan AhoSource :
- International psychogeriatrics [ 1041-6102 ] ; 2005.
Descripteurs français
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Adaptation, Psychological (drug effects), Aged, Aged, 80 and over, Analysis of Variance, Antipsychotic Agents (administration & dosage), Canada (epidemiology), Dementia (drug therapy), Humans, Life Change Events, Long-Term Care (psychology), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Patient Transfer, Prevalence, Residential Facilities, Stress, Psychological (drug therapy), Stress, Psychological (epidemiology), Stress, Psychological (etiology).
- MESH :
- chemical , administration & dosage : Antipsychotic Agents.
- geographic , epidemiology : Canada.
- drug effects : Adaptation, Psychological.
- drug therapy : Dementia, Parkinson Disease, Stress, Psychological.
- epidemiology : Parkinson Disease, Stress, Psychological.
- etiology : Stress, Psychological.
- psychology : Long-Term Care.
- Aged, Aged, 80 and over, Analysis of Variance, Humans, Life Change Events, Patient Transfer, Prevalence, Residential Facilities.
Abstract
Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation.
PubMed: 16050429
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16050429Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.</title><author><name sortKey="Hagen, Brad" sort="Hagen, Brad" uniqKey="Hagen B" first="Brad" last="Hagen">Brad Hagen</name><affiliation wicri:level="1"><nlm:affiliation>School of Health Sciences, The University of Lethbridge, 4401 University Drive, Lethbridge, Alberta T1K 3M4, Canada. brad.hagen@uleth.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Health Sciences, The University of Lethbridge, 4401 University Drive, Lethbridge, Alberta T1K 3M4</wicri:regionArea><wicri:noRegion>Alberta T1K 3M4</wicri:noRegion></affiliation></author><author><name sortKey="Esther, Chris Armstrong" sort="Esther, Chris Armstrong" uniqKey="Esther C" first="Chris Armstrong" last="Esther">Chris Armstrong Esther</name></author><author><name sortKey="Ikuta, Roland" sort="Ikuta, Roland" uniqKey="Ikuta R" first="Roland" last="Ikuta">Roland Ikuta</name></author><author><name sortKey="Williams, Robert J" sort="Williams, Robert J" uniqKey="Williams R" first="Robert J" last="Williams">Robert J. Williams</name></author><author><name sortKey="Le Navenec, Carole Lynne" sort="Le Navenec, Carole Lynne" uniqKey="Le Navenec C" first="Carole-Lynne" last="Le Navenec">Carole-Lynne Le Navenec</name></author><author><name sortKey="Aho, Morgan" sort="Aho, Morgan" uniqKey="Aho M" first="Morgan" last="Aho">Morgan Aho</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16050429</idno><idno type="pmid">16050429</idno><idno type="wicri:Area/PubMed/Corpus">001261</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001261</idno><idno type="wicri:Area/PubMed/Curation">001261</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001261</idno><idno type="wicri:Area/PubMed/Checkpoint">001261</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001261</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.</title><author><name sortKey="Hagen, Brad" sort="Hagen, Brad" uniqKey="Hagen B" first="Brad" last="Hagen">Brad Hagen</name><affiliation wicri:level="1"><nlm:affiliation>School of Health Sciences, The University of Lethbridge, 4401 University Drive, Lethbridge, Alberta T1K 3M4, Canada. brad.hagen@uleth.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>School of Health Sciences, The University of Lethbridge, 4401 University Drive, Lethbridge, Alberta T1K 3M4</wicri:regionArea><wicri:noRegion>Alberta T1K 3M4</wicri:noRegion></affiliation></author><author><name sortKey="Esther, Chris Armstrong" sort="Esther, Chris Armstrong" uniqKey="Esther C" first="Chris Armstrong" last="Esther">Chris Armstrong Esther</name></author><author><name sortKey="Ikuta, Roland" sort="Ikuta, Roland" uniqKey="Ikuta R" first="Roland" last="Ikuta">Roland Ikuta</name></author><author><name sortKey="Williams, Robert J" sort="Williams, Robert J" uniqKey="Williams R" first="Robert J" last="Williams">Robert J. Williams</name></author><author><name sortKey="Le Navenec, Carole Lynne" sort="Le Navenec, Carole Lynne" uniqKey="Le Navenec C" first="Carole-Lynne" last="Le Navenec">Carole-Lynne Le Navenec</name></author><author><name sortKey="Aho, Morgan" sort="Aho, Morgan" uniqKey="Aho M" first="Morgan" last="Aho">Morgan Aho</name></author></analytic><series><title level="j">International psychogeriatrics</title><idno type="ISSN">1041-6102</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Psychological (drug effects)</term><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Antipsychotic Agents (administration & dosage)</term><term>Canada (epidemiology)</term><term>Dementia (drug therapy)</term><term>Humans</term><term>Life Change Events</term><term>Long-Term Care (psychology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Patient Transfer</term><term>Prevalence</term><term>Residential Facilities</term><term>Stress, Psychological (drug therapy)</term><term>Stress, Psychological (epidemiology)</term><term>Stress, Psychological (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Adaptation, Psychological</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dementia</term><term>Parkinson Disease</term><term>Stress, Psychological</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term><term>Stress, Psychological</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Stress, Psychological</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Long-Term Care</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Analysis of Variance</term><term>Humans</term><term>Life Change Events</term><term>Patient Transfer</term><term>Prevalence</term><term>Residential Facilities</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16050429</PMID><DateCreated><Year>2005</Year><Month>07</Month><Day>29</Day></DateCreated><DateCompleted><Year>2005</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1041-6102</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International psychogeriatrics</Title><ISOAbbreviation>Int Psychogeriatr</ISOAbbreviation></Journal><ArticleTitle>Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.</ArticleTitle><Pagination><MedlinePgn>179-93</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Data on antipsychotic use were collected in two Canadian long-term care (LTC) facilities. During the one-year study, residents in one facility were relocated to a new facility, allowing examination of the changes in antipsychotic use associated with relocation.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A comparative descriptive design was used. Pharmacy and chart data on antipsychotic use were gathered for three separate one-month periods during one year. Data were collected both in a facility experiencing relocation of all residents to a new facility, and in a facility not undergoing relocation. The three one-month data collection periods covered a one-month period before the relocation, immediately after the relocation, and six months after the relocation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the facility not experiencing relocation, an average of 31.3% of all residents were receiving antipsychotics. Residents in this facility received antipsychotics for an average length of 0.81 years, and 20.8% of all antipsychotic prescriptions reflected dose reductions within six months of the start of the prescription. Only 8.1% of prescriptions had accompanying documentation on the behavioral indication for the use of antipsychotics. A total of 73.4% of all antipsychotics were 'atypical' antipsychotics, and 13.5% of all antipsychotic prescriptions were written as 'p.r.n.' (as needed). While the use of antipsychotics remained relatively constant in the non-relocation facility (between 30.3% and 33.1% of all residents), the percentage of residents receiving antipsychotics in the facility experiencing a relocation climbed significantly; from 21.5% six months before the move, to 32.6% immediately after the move, to 36.9% six months after the move.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings, when compared with the U.S. standards on antipsychotic use (OBRA), suggest the need for additional research on antipsychotic use in Canadian LTC facilities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hagen</LastName><ForeName>Brad</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Health Sciences, The University of Lethbridge, 4401 University Drive, Lethbridge, Alberta T1K 3M4, Canada. brad.hagen@uleth.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esther</LastName><ForeName>Chris Armstrong</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Ikuta</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Le Navenec</LastName><ForeName>Carole-Lynne</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Morgan</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int Psychogeriatr</MedlineTA><NlmUniqueID>9007918</NlmUniqueID><ISSNLinking>1041-6102</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010360" MajorTopicYN="Y">Patient Transfer</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012112" MajorTopicYN="Y">Residential Facilities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16050429</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Aho, Morgan" sort="Aho, Morgan" uniqKey="Aho M" first="Morgan" last="Aho">Morgan Aho</name><name sortKey="Esther, Chris Armstrong" sort="Esther, Chris Armstrong" uniqKey="Esther C" first="Chris Armstrong" last="Esther">Chris Armstrong Esther</name><name sortKey="Ikuta, Roland" sort="Ikuta, Roland" uniqKey="Ikuta R" first="Roland" last="Ikuta">Roland Ikuta</name><name sortKey="Le Navenec, Carole Lynne" sort="Le Navenec, Carole Lynne" uniqKey="Le Navenec C" first="Carole-Lynne" last="Le Navenec">Carole-Lynne Le Navenec</name><name sortKey="Williams, Robert J" sort="Williams, Robert J" uniqKey="Williams R" first="Robert J" last="Williams">Robert J. Williams</name></noCountry><country name="Canada"><noRegion><name sortKey="Hagen, Brad" sort="Hagen, Brad" uniqKey="Hagen B" first="Brad" last="Hagen">Brad Hagen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001252 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001252 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16050429
|texte= Antipsychotic drug use in Canadian long-term care facilities: prevalence, and patterns following resident relocation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16050429" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |